Survival among Dually Infected HIV Patients Compared to HIV-1 Mono-Infected Patients Receiving ART in Senegal: A Twelve-Year Cohort Study
Journal Title: International Journal of Virology and AIDS - Year 2016, Vol 3, Issue 1
Abstract
In West Africa, HIV-2 single infection (HIV-2s) and HIV-1 + HIV-2 dual infection (HIV-D) remain endemic but their morbidity is progressively decreasing. Among HIV-D infected patients receiving antiretroviral therapy (ART), data on mortality are very scarce. The purpose of this analysis was to compare survival of HIV-D infected with that of HIV-1 singly infected (HIV-1s) patients over twelve years of follow up after ART initiation.
Authors and Affiliations
Keywords
Related Articles
- EP ID EP353889
- DOI 10.23937/2469-567X/1510022
- Views 124
- Downloads 0
HIV Exposed Uninfected Children at School Age: Developing Country Context
With the success of chemoprophylaxis for the prevention of perinatal transmission of the human immunodeficiency virus (HIV), an increasing number of HIV-exposed but uninfected (HEU) children will have in utero and post-p...
Successful Treatment of Chronic Hepatitis C using Pegylated Interferon and Ribavirin in a Patient with Sheehan's Syndrome
A 50-year-old female with Sheehan's syndrome was treated for chronic hepatitis C using pegylated interferon-α2b and ribavirin. The patient's HCV-RNA status was negative by the fourth week and remained undetectable until...
The Monitoring of Lymphocyte Populations may be Optional in Patients with Suppressed Viremia: A Two Years Observational Study
The determination of lymphocyte populations (LPs) traditionally has been included in the routine follow-up of HIV-infected patients as an indicator of the degree of immune suppression and of the need to start treatment,...
Non Alcoholic Fatty Liver Disease and Bone Fractures in Patients with HIV
Human immunodeficiency virus infection has posed a challenge for mankind and now this disease is more of a challenge for quality of life than for virus related mortality. This review aims to study two prevalent diseases...
PrEP Works, But Only When You [Have Access to] Take it: Improving PrEP Access for Young People in Chicago and Philadelphia
The 2012 United States Food and Drug Administration approval of Tenofovir/Emtricitabine for HIV pre-exposure prophylaxis (PrEP) has added a highly effective, safe biomedical option to the HIV prevention toolbox. In the U...